Clinical trial
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
NCT00005652 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
- Lead sponsor
- University of Alabama at Birmingham
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2000
- Completion date
- Not reported
- Enrollment
- 20
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.